Outcomes of Surgically Implanted Impella Microaxial Flow Pumps in Heart Failure-Related Cardiogenic Shock
Journal of Cardiac Failure · 2026-06 · 32 (6) · 969-979
DOI: 10.1016/j.cardfail.2025.03.008 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cardiac Failure, 2026-06. Verfasst von Jacob Abraham und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cardiovascular Analytics, Research, & Data Science (CARDS), Providence St. Joseph Research Network, Portland, OR. Electronic address: Jaco…. Hauptthemen laut MEDLINE: Heart-Assist Devices, Shock, Cardiogenic, Heart Failure. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Abbott Pharmaceuticals, Johnson and Johnson.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Patients with cardiogenic shock (CS) are increasingly treated with high-profile microaxial flow pumps (Impella 5.5), but little is known about the indications and outcomes of this support strategy in patients with CS due to heart failure (HF-CS). OBJECTIVES: We sought to describe the clinical features and outcomes of patients with HF-CS treated with Impella 5.5. METHODS: We analyzed data from a prospective, multicenter observational study of patients with CS who had been implanted with an Impella 5.5. Adverse events, in-hospital survival rates and 6- and 12-month survival rates were analyzed in the total cohort and between patients treated with Impella 5.5 alone or with multiple temporary mechanical circulatory support (tMCS) devices. Outcomes were stratified based on native heart survival (NHS) and heart-replacement therapy (HRT). RESULTS: Of the 804 patients with CS who received Impella 5.5, 444 had HF-CS. Prior to Impella 5.5 placement, 214 (48.1%) had received other tMCS devices. The duration of Impella support was 21.1 ± 20.1 days (median: 15; IQR: 8, 26 days). Survival to discharge was 75.0% for the total cohort, 86.5% for those receiving Impella 5.5 alone, and 65.0% for those receiving multiple tMCS devices. The need for renal-replacement therapy and thrombocytopenia requiring transfusions was more common in those receiving multiple tMCS devices. Among patients with NHS, 6- and 12-month survival rates were 71.3% and 64.4%, respectively, while patients receiving HRT had survival rates > 93%. CONCLUSIONS: Patients with HF-CS treated with Impella 5.5 had overall favorable in-hospital, 6-month and 12-month survival, both as a bridge to NHS as HRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Cardiovascular Analytics, Research, & Data Science (CARDS), Providence St. Joseph Research Network, Portland, OR. Electronic address: Jacob.Abraham@providence.org.
- Hackensack University Medical Center, Hackensack, NJ.
- Department of Cardiac Surgery, Florida Hospital, Orlando, FL.
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.
- Division of Cardiovascular and Thoracic Surgery, University of Texas at Austin Dell Medical School, Austin, Texas.
- University of California at Los Angeles, Los Angeles, CA.
Förderung
- Abbott Pharmaceuticals
- Johnson and Johnson
Zitieren
APA
Abraham, J., Anderson, M., Silvestry, S., Soltesz, E. G., Ono, M., Mody, K., Esmailian, F., Kilic, A., Bharmi, R., Chhim, R., Bogaev-Chapman, R., Katlaps, G. J., Armas, I. S., Daneshmand, M. A., Kaczorowski, D. J., Pham, D. T., Ramzy, D., & D'Alessandro, D. (2026). Outcomes of Surgically Implanted Impella Microaxial Flow Pumps in Heart Failure-Related Cardiogenic Shock. Journal of Cardiac Failure, 32(6), 969-979. https://doi.org/10.1016/j.cardfail.2025.03.008
Vancouver
Abraham J, Anderson M, Silvestry S, Soltesz EG, Ono M, Mody K, et al. Outcomes of Surgically Implanted Impella Microaxial Flow Pumps in Heart Failure-Related Cardiogenic Shock. Journal of Cardiac Failure. 2026;32(6):969-979. doi:10.1016/j.cardfail.2025.03.008
BibTeX
@article{Abraham2026,
author = {Abraham, Jacob and Anderson, Mark and Silvestry, Scott and Soltesz, Edward G and Ono, Masahiro and Mody, Kanika and Esmailian, Fardad and Kilic, Arman and Bharmi, Rupinder and Chhim, Rothy and Bogaev-Chapman, Roberta and Katlaps, Gundars J and Armas, Ismael Salas DE and Daneshmand, Mani A and Kaczorowski, David J and Pham, Duc Thinh and Ramzy, Danny and D'Alessandro, David},
title = {Outcomes of Surgically Implanted Impella Microaxial Flow Pumps in Heart Failure-Related Cardiogenic Shock},
journal = {Journal of Cardiac Failure},
year = {2026},
volume = {32},
number = {6},
pages = {969--979},
doi = {10.1016/j.cardfail.2025.03.008}
}
EUVIMED